Nautilus Biotechnology, Inc. (NASDAQ:NAUT) Q2 2022 Earnings Conference Call August 2, 2022 8:30 AM ET Company Participants Sujal Patel - Founder and Chief Executive Officer Anna Mowry - Chief Financial Officer Parag Mallick - Founder and Chief Scientist Conference Call Participants Stephanie Yan - Cowen and Company, LLC Tejas Savant - Morgan Stanley David Delahunt - Goldman Sachs Operator Thank you for standing by, and welcome to the Nautilus Biotechnology Second Quarter 2022 Earnings Conference Call. At th ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 OR Delaware 98-1541723 (State or other jurisdiction of incorporation or organization) 2701 Eastlake Avenue East Seattle, Washington 98102 (Address of principal executive offices) (Zip Code) (206) 333-2001 o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ...

Nautilus Biotechnology, Inc. (NASDAQ:NAUT) Q1 2022 Earnings Conference Call May 3, 2022 8:30 AM ET Company Participants Sujal Patel - Co-Founder & CEO Anna Mowry - CFO Parag Mallick - Co-Founder & Chief Scientific Officer Conference Call Participants Matt Kim - Jefferies Stephanie Yan - Cowen & Company Edmund Tu - Morgan Stanley David Delahunt - Goldman Sachs Operator Thank you for standing by, and welcome to the Nautilus Q1 2022 Earnings Conference Call. At this time, all participants are in a listen-only ...

Nautilus Biotechnology, Inc. (NASDAQ:NAUT) Q4 2021 Earnings Conference Call February 24, 2022 8:30 AM ET Company Participants Sujal Patel - Co-Founder & Chief Executive Officer Parag Mallick - Co-Founder & Chief Scientific Officer Anna Mowry - Chief Financial Officer Conference Call Participants Max Masucci - Cowen & Company Matthew Sykes - Goldman Sachs Operator Good morning, ladies and gentlemen. Thank you for standing by and welcome to Nautilus Biotechnology Fourth Quarter 2021 Earnings Conference Call. ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 __________________________________________________________________________ FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___________ to ___________ Commission file number 001-39434 NAUTILUS BIOTECHNOLOGY, INC. (Exact nam ...

In C Delivering on the Promise of the Proteome FEBRUARY, 2022 Safe harbor This presentation and the accompanying oral presentation contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, among others, statements regarding the size and growth of the protein analysis market; Nautilus Biotechnology's anticipated total addressable market; the performance of Nautilus Biotechnology's proteomics technology platform; Nautilus Biotechnology's business ...

x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) For the transition period from _________ to _________ Commission File Number 001-39434 NAUTILUS BIOTECHNOLOGY, INC. (Exact name of registrant as specified in its charter) Delaware 98-15 ...

Nautilus Biotechnology, Inc. (NASDAQ:NAUT) Q3 2021 Earnings Conference Call November 2, 2021 8:30 AM ET Company Participants Sujal Patel - Co-Founder & Chief Executive Officer Parag Mallick - Co-Founder & Chief Scientific Officer Anna Mowry - Chief Financial Officer Conference Call Participants Brandon Couillard - Jefferies Operator Good day and thank you for standing by. Welcome to the Nautilus Third Quarter 2021 Earnings Conference Call. At this time all participants are in a listen-only mode. After the s ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _________ to _________ Commission File Number 001-39434 NAUTILUS BIOTECHNOLOGY, INC. (Exact name of registrant as specified in its charter) Delaware 98-1541723 ...

Nautilus Biotechnology, Inc. (NASDAQ:NAUT) Q2 2021 Earnings Conference Call August 10, 2021 8:00 AM ET Company Participants Sujal Patel ??? Co-Founder and Chief Executive Officer Parag Mallick ??? Co-Founder and Chief Scientist Anna Mowry ??? Chief Financial Officer Conference Call Participants Brandon Couillard ??? Jefferies Matt Sykes ??? Goldman Sachs Tejas Savant ??? Morgan Stanley Operator Good morning and thank you for standing by. Welcome to the Nautilus Biotechnology's Second Quarter 2021 Earnings C ...